HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
48 hedge funds and large institutions have $37M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 17 closing their positions.
1,400% more call options, than puts
Call options by funds: $30K | Put options by funds: $2K
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
11% less funds holding
Funds holding: 54 → 48 (-6)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
45% less capital invested
Capital invested by funds: $67M → $37M (-$30M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$7.37M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.68M |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$690K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$472K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWP
Private Wealth Partners
Mill Valley,
California
|
-$5.05M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$1.09M |
| 3 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
-$1.04M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.01M |
| 5 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$1.01M |
HTGM Hedge Fund Activity: Q4 2018 in Review
48 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q4 2018, worth a combined $37M — down 45% from $67M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of HTGM and 12 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 16 added.
The largest buyer was Stonepine Capital Management, adding an estimated $7.37M. The largest seller was Private Wealth Partners, exiting entirely with an estimated $5.05M sold.
- 48 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q4 2018, down from 54 in Q3 2018.
- Funds reported $37M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q4 2018, down 45% quarter-over-quarter.
- 12 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q4 2018 and 17 closed out, a net change of -5 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q4 2018 was Stonepine Capital Management, an estimated $7.37M added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q4 2018 was Private Wealth Partners, an estimated $5.05M sold.
Based on aggregated 13F filings for Q4 2018.